Breakthrough trial aims to prevent inherited amyloidosis in young adults
Prevention
Recruiting now
This study tests an experimental drug called acoramidis in 587 adults aged 18–75 who carry a faulty gene that causes transthyretin amyloidosis (ATTR) but have no symptoms yet. The drug aims to stabilize a key protein and prevent or delay the buildup of harmful plaques in the hear…
Phase: PHASE3 • Sponsor: Eidos Therapeutics, a BridgeBio company • Aim: Prevention
Last updated May 26, 2026 10:29 UTC